literature

HIV mutation literature information.

Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients.

PMID: 35082353 2022 Scientific reports

Discussion: In this regard, a previous study demonstrated that the emergence of protease major resistance mutation I50V require as a prerequisite changes in the Gag gene at position L449 in vivo and cause reduction of sensitivity to amprenavir and an improved viral fitness in vitro.

Discussion: Several studies have shown a positive correlation of Gag P453L mutation with some protease major resistance mutations such as I50V and I84V.

Discussion: These major protease mutations I50V and L90M would therefore be a sentinel for the L449F in the

Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.

PMID: 34897227 2022 Journal of acquired immune deficiency syndromes (1999)

Table: I50L/V

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.

PMID: 34694878 2022 Antimicrobial agents and chemotherapy

Table: I50I/V

Table: I50V

Investigating potency of TMC-126 against wild-type and mutant variants of HIV-1 protease: a molecular dynamics and free energy study.

PMID: 34787532 2021 SAR and QSAR in environmental research

Abstract: Our study reveals that the flap of PR1 adopts a semi-open conformation due to the mutation I50V or MDR20.

Abstract: The potency of the inhibitor decreases in the order: wild type PR1 > M46L > MDR20 > I50V > PR2 > V32I > A28S.

Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study.

PMID: 34622871 2021 Medicine

Result: There were no other mutations at L76 V, I47 V, I50 V, I54 M/L, or I84 V.

Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV.

PMID: 34289404 2021 International journal of antimicrobial agents

Abstract: The only patient (1.3%) with virological failure at Week 48 had poor adherence and baseline low-level resistance to darunavir with resistance-associated mutations at M46L, I50V and V82A.

Reverse transcriptase and protease inhibitors mutational viral load in HIV infected pregnant women with transmitted drug resistance in Argentina.

PMID: 34085506 2021 Revista espanola de quimioterapia

Abstract: Most frequent PI-RAMs were I85V, M46I, I50V and L90M (n=2, 5% each).

Result: Most frequent PI-RAMS were I85V, M46I, I50V and L90M (n=2, 5% each), all of them with modest impact in the activity of currently available PIs.

Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.

PMID: 33805099 2021 Biomolecules

Introduction: Research shows that the emergence of V32I, L33F, I47A, I50V, L76V, and 184V under drug pressure during LPV therapy may confer cross-resistance to DRV.

Introduction: The major HIV-1 PI resistance mutations that affect the efficacy of boosted LPV regimen are V32I, L33F, M46I/L, I47V/A, I50V, I54V/T/A/L/M, L76V, V82A/F/T/S, I84V.

HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.

PMID: 33668946 2021 Pathogens (Basel, Switzerland)

Result: Other PI-related mutations such as L10F, I47V, I50V, F53L, I54VT and N83D have the mutation frequency of about 2%.

Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.

PMID: 31965175 2020 The Journal of infectious diseases

Abstract: In PR, 12 nonpolymorphic TSMs occurred in >=11 persons: V33I, K45R, V47A, I50V, I54M, T56V, V62A, A73G, I82F, I84V, F85L, L90M.

Browser Board

Co-occurred Entities

Filtrator